Long Time Survival after Reduced Chemotherapy in a 15-year-old Patient with AML and Candida Krusei Sepsis and Eye Involvement

B. Bernbeck,G. Janssen,S. Winterhalter,D. Schneider,R. Wessalowski
DOI: https://doi.org/10.1055/s-0029-1239536
2009-11-01
Klinische Pädiatrie
Abstract:A 15-year-old boy with AML develops a fulminant candida krusei sepsis complicated by acute blindness due to enophthalmitis and subsequent bleeding during prolonged pancytopenia after induction therapy. Despite a low dose prophylaxis with oral nystatine and i. v. amphotericin B (ampho B) three times a week (0.8 mg/kg). Under an early intensified therapy with ampho B (1.5 mg/kg/d) combined with 5-flucytosin (160 mg/kg/d)the sepsis could be controlled and visual acuity slowly improved. A vitrectomy is due to the bleeding unavoidable. Despite a therapy delay of 4 weeks and omission of two cycles of the intensification treatment the patient is in continuous complete remission for longer than 10 years after diagnosis. If it is within the treatment protocols manageable to detect patients with increased sensitivity against cytostatic drugs and correspondingly highly sensitive leukemic cells, such complications could be avoided due to primary treatment adaptation.
What problem does this paper attempt to address?